Overview

A class action lawsuit has been filed against Zoetis, Inc.  (“Zoetis” or the “Company”) (NYSE : ZTS) and certain of the Company’s senior executive officers (collectively, “Defendants”) alleging violations of the federal securities laws. The Zoetis lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Zoetis securities between January 14, 2025, and May 6, 2025, inclusive (the “Class Period”). Investors have until July 27, 2026, to seek appointment as lead plaintiff of the Zoetis class action lawsuit.

Zoetis is a leading animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. During the Class Period, the Company’s Companion Animal segment, including flagship products Librela, Apoquel, Cytopoint, and Simparica Trio, served as Zoetis’ primary growth engine and accounted for the majority of its revenue.

According to the complaint, Defendants repeatedly represented that Zoetis’ flagship Companion Animal products continued to benefit from strong veterinarian adoption, growing market share, and durable long-term growth. The complaint alleges that these statements were materially false and misleading because veterinarian adoption of Librela was allegedly weakening following FDA safety warnings concerning serious neurological adverse events, while Zoetis’ dermatology and parasiticide franchises were purportedly losing market share to lower-priced competing products.

The truth began to emerge on August 5, 2025, when Zoetis reported second-quarter 2025 results that revealed weakening demand trends within its Companion Animal business. Although the Company raised full-year guidance, analysts focused on softness in the Company’s pain management franchise and concerns regarding the sustainability of future growth. On this news, Zoetis’ stock price fell nearly 4%.

Then on November 4, 2025, Zoetis reported third-quarter 2025 results showing slowing growth across key Companion Animal franchises and it lowered its full-year sales outlook. The Company disclosed continued weakness in Librela sales and increasing competitive pressure in dermatology and parasiticides. On this news, Zoetis’ stock price declined nearly 14%. On February 12, 2026, Zoetis reported fourth-quarter and full-year 2025 results and provided 2026 guidance reflecting continued slowing growth and increasing competitive pressures affecting its Companion Animal portfolio. On this news, Zoetis’ stock price fell approximately 2.4%.

Then, on May 7, 2026, Zoetis reported first-quarter 2026 financial results reflecting significant deterioration across its Companion Animal business and sharply reduced its full-year guidance. The Company acknowledged intensified competition in key pet care categories and increased price sensitivity among customers, market-share losses in dermatology, and contraction in the parasiticides market. Following these disclosures, Zoetis’ stock price fell more than 21%.

*          *          *

If you purchased or otherwise acquired Zoetis securities between January 14, 2025, and May 6, 2026, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Zoetis class action lawsuit is July 27, 2026.